European Perspective on Multiple Myeloma Treatment Strategies in 2014.
Ludwig H et al. Oncologist. 2014 Jul 25. pii: theoncologist.2014-0042. [Epub ahead of print].

The roles of consolidation and maintenance therapy with novel agents after autologous stem cell transplantation in patients with multiple myeloma.
Joks M et al. Eur J Haematol. 2014 Jul 10. doi: 10.1111/ejh.12412. [Epub ahead of print].

Pharmacoeconomic Implications of Lenalidomide Maintenance Therapy in Multiple Myeloma.
Kim MY et al. Oncology. 2014 Jul 18;87(4):224-231. [Epub ahead of print].

Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment.
Zago M et al. Ann Hematol. 2014 Jul 1. [Epub ahead of print].

Cost effectiveness analysis of early versus late autologous stem cell transplantation (ASCT) in multiple myeloma (MM).
Pandya C et al. Clin Transplant. 2014 Jul 17. doi: 10.1111/ctr.12421. [Epub ahead of print].

Drug assessment by a Pharmacy and Therapeutics committee: from drug selection criteria to use in clinical practice.
Lozano-Blázquez A et al. Ther Clin Risk Manag. 2014 Jul 9;10:527-35. doi: 10.2147/TCRM.S62572. eCollection 2014.

Systemic lupus erythematosus is associated with increased incidence of hematologic malignancies: A meta-analysis of prospective cohort studies.
Apor E et al. Leuk Res. 2014 Jul 10. pii: S0145-2126(14)00204-5. doi: 10.1016/j.leukres.2014.06.025. [Epub ahead of print].

Subcutaneous bortezomib for multiple myeloma treatment: patients’ benefits.
Petrucci MT et al. Patient Prefer Adherence. 2014 Jul 4;8:939-46. doi: 10.2147/PPA.S38142. eCollection 2014.

Efficacy and safety of lenalidomide in relapse/refractory multiple myeloma-Real life experience of a tertiary cancer center.
João C et al. Ann Hematol. 2014 Jul 20. [Epub ahead of print].

Farm residence and lymphohematopoietic cancers in the Iowa Women׳s Health Study.
Jones RR et al. Environ Res. 2014 Jul 16;133C:353-361. doi: 10.1016/j.envres.2014.05.028. [Epub ahead of print].

Survival for haematological malignancies in Europe between 1997 and 2008 by region and age: results of EUROCARE-5, a population-based study.
Sant M et al. Lancet Oncol. 2014 Jul 11. pii: S1470-2045(14)70282-7. doi: 10.1016/S1470-2045(14)70282-7. [Epub ahead of print].

Still a long way to go to achieve multidisciplinarity for the benefit of patients: commentary on the ESMO position paper (Annals Oncology Jan;25(1): 9-15, 2014).
Valentini V et al. Ann Oncol. 2014 Jul 10. pii: mdu245. [Epub ahead of print].

Understanding what matters most to people with multiple myeloma: a qualitative study of views on quality of life.
Osborne TR et al. BMC Cancer. 2014 Jul 9;14(1):496. doi: 10.1186/1471-2407-14-496.

The use of novel drugs can effectively improve response, delay relapse and enhance overall survival in multiple myeloma patients with renal impairment.
Uttervall K et al. PLoS One. 2014 Jul 8;9(7):e101819. doi: 10.1371/journal.pone.0101819. eCollection 2014.

Age and aging in blood disorders: multiple myeloma.
Zweegman S et al. Haematologica. 2014 Jul;99(7):1133-7. doi: 10.3324/haematol.2014.110296.

Medication use and multiple myeloma risk in Los Angeles County.
Nuyujukian DS et al. Cancer Causes Control. 2014 Jul 1. [Epub ahead of print].

Older adults newly diagnosed with symptomatic myeloma and treatment decision making.
Tariman JD et al. Oncol Nurs Forum. 2014 Jul 1;41(4):411-9. doi: 10.1188/14.ONF.411-419.